Page last updated: 2024-08-22

platinum and Kidney Diseases

platinum has been researched along with Kidney Diseases in 50 studies

Research

Studies (50)

Timeframe	Studies, this research(%)	All Research%
pre-1990	12 (24.00)	18.7374
1990's	12 (24.00)	18.2507
2000's	9 (18.00)	29.6817
2010's	14 (28.00)	24.3611
2020's	3 (6.00)	2.80

Authors

Authors	Studies
Chen, X; Chu, B; Feng, S; He, Q; He, Y; Huang, Z; Li, P; Lin, T; Qian, Z; Qu, Y; Wang, P; Yang, Z	1
Funakoshi, T; Hira, D; Horimatsu, T; Imai, S; Itohara, K; Kataoka, S; Matsubara, K; Matsubara, T; Muto, M; Nakagawa, S; Nakagawa, T; Shimazaki, A; Terada, T; Yanagita, M; Yonezawa, A	1
Casanova, AG; Cruz, JJ; Cruz-González, I; Del Barco, E; Hernández-Sánchez, MT; López-Hernández, FJ; Martínez-Salgado, C; Morales, AI; Ortiz, A; Pescador, M; Prieto, M; Ramis, LM; Rihuete, MI; Vicente-Vicente, L	1
Furugen, A; Iseki, K; Kobayashi, M; Narumi, K; Okamoto, K; Saito, Y; Yamada, T	1
Akimoto, Y; Daibo, T; Ishida, I; Isoda, K; Kawakami, H; Nishimura, T; Taira, I; Taira, Y; Tsutsumi, Y; Yanoshita, R; Yoshioka, Y; Yushina, K	1
Cai, GY; Chen, XM; Duan, ZY; Li, JJ; Liu, JQ; Yin, P	1
Anai, S; Iwama, E; Nakanishi, Y; Okamoto, I; Otsubo, K; Tanaka, K; Yoneshima, Y	1
Cvijanović, O; Domitrović, R; Mahmutefendić, H; Pugel, EP; Škoda, M; Zagorac, GB	1
Cougnon, M; Duranton, C; Melis, N; Mograbi, B; Rubera, I; Tauc, M	1
Chen, J; Gu, X; Liang, W; Sun, X; Wang, J	1
Bachy, E; Bouafia-Sauvy, F; Gyan, E; Iltis, A; Ranchon, F; Rioufol, C; Salles, G; Sarkozy, C; Schwiertz, V; Tixier, F; Tournamille, JF; Vantard, N	1
Abdelghany, TM; Abo-Saif, AA; Abo-Youssef, AM; Darwish, MA; Khalaf, MM; Saleh, IG	1
Basso, U; Basterretxea, L; Bielle, J; Del Muro, XG; Guillot, A; Houédé, N; Lainez, N; Locker, G; Lucas, C; Lusuardi, L; Morelli, F; Parra, HS; Spaeth, D; Tambaro, R; Theodore, C; Tonini, G	1
Cai, S; Cohen, MS; Davies, NM; Forrest, ML; Xie, Y	1
am Zehnhoff-Dinnesen, A; Ciarimboli, G; Deuster, D; Edemir, B; Holtkamp, M; Jürgens, H; Knief, A; Koepsell, H; Lanvers-Kaminsky, C; Pavenstädt, H; Schinkel, AH; Schlatter, E; Sperling, M	1
Aleksunes, LM; Goedken, MJ; Klaassen, CD; Manautou, JE; Rockwell, CE; Thomale, J	1
Blanco González, E; García Sar, D; Montes-Bayón, M; Sanz-Medel, A; Sierra Zapico, LM	1
Cacini, W; Sarangarajan, R	1
Abdel-Maksoud, S; Ahmed, WA; Badary, OA; Owieda, GH	1
Bakalova, A; Buyukliev, R; Ivanov, D; Karaivanova, M; Konstantinov, S; Momekov, G; Todorov, D	1
Boos, J; Deuster, D; Dinnesen, AG; Jaehde, U; Krefeld, B; Lanvers-Kaminsky, C; Pieck, AC; Seifert, E; Würthwein, G	1
Areberg, J; Björkman, S; Johansson, L; Johnsson, A; Mattsson, S; Norrgren, K; Sjölin, M	1
Doroshow, JH; Egorin, MJ; Goetz, A; Graham, MA; Greenslade, D; Grem, JL; Hamilton, A; Ivy, P; Lockwood, G; Mani, S; Mulkerin, DL; Ng, CM; Ramanathan, RK; Remick, SC; Sharma, S; Synold, TW; Takimoto, CH	1
Mays, CW	1
Aggarwal, SK; Broomhead, JA; Fairlie, DP; Whitehouse, MW	1
Guo, JH; Song, ST; Xu, ZL	1
Hirota, S; Sadzuka, Y; Shimizu, Y; Takino, Y	1
Ali-Osman, F; Khokhar, AR; Kido, Y; Siddik, ZH; Yoshida, M	1
Cacini, W; Harden, EA; Skau, KA	1
Ansieau, JP; Beaujeux, R; Bourjat, P; Jacqmin, D; Jahn, C; Lebras, Y; Oswald, P; Roy, C; Saussine, C	1
Dulberg, CS; Goel, R; Mikhael, NZ; Montpetit, VA; Redmond, MD; Stewart, DJ	1
Appenroth, D; Fröb, S; Kersten, L; Splinter, FK; Winnefeld, K	1
Boven, E; Gall, HE; van der Vijgh, WJ; Vermorken, JB; Welink, J	1
Hanada, K; Kudo, A; Odaka, K; Ogata, H	1
Husain, K; Malafa, M; Rybak, LP; Somani, SM; Trammell, GL; Whitworth, C	1
Erdlenbruch, B; Grunewald, RW; Kern, W; Lakomek, M; Pekrum, A; Roth, C	1
Hanigan, MH; Townsend, DM	1
DeWoskin, RS; Riviere, JE	1
Basinger, MA; Holscher, MA; Jones, MM	1
Baumann, K; Hannemann, J	1
Bakhteeva, VT; Brovtsyn, VK; Myazina, EM; Reznik, LV	1
Hayashi, T; Katahira, J; Kitayama, R; Kumada, T; Kumano, K; Muratani, T; Saikawa, I; Shimizu, K; Watanabe, Y; Yasuda, T	1
Basinger, MA; Jones, MM	1
Bergers, JJ; Claessen, A; de Groot, G; de Jong, WH; Franken, MA; Steerenberg, PA; Storm, G; van Hoesel, QG; Wubs, KL	1
Amarin, J; Blackie, RG; Farmer, JG; Harding, M; Harland, SJ; Kaye, SB; Kerr, DJ	1
Basinger, MA; Bradley, CA; Jones, MM; Mitchell, WM	1
Aggarwal, SK; Batzer, MA	1
Ishikawa, E; Shimizu, E; Tanaka, H; Teshima, S	1
Jongejan, HT; Molenaar, JC; Provoost, AP; Wolff, ED	1
Alcock, N; Kelsen, DP; Young, CW	1

Reviews

1 review(s) available for platinum and Kidney Diseases

Article	Year
Impact of aging on the risk of platinum-related renal toxicity: A systematic review and meta-analysis. Cancer treatment reviews, 2018, Volume: 69 Topics: Aged; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Kidney Diseases; Neoplasms; Platinum; Prognosis	2018

Trials

2 trial(s) available for platinum and Kidney Diseases

Article	Year
Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Creatinine; Cyclobutanes; Erythrocytes; Female; Half-Life; Humans; Kidney Diseases; Liver Diseases; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Platelet Count; Platinum; Stereoisomerism	1999
Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions. Pediatric nephrology (Berlin, Germany), 2001, Volume: 16, Issue:7 Topics: Adolescent; Antineoplastic Agents; Area Under Curve; Biomarkers; Child; Child, Preschool; Cisplatin; Female; Half-Life; Humans; Infusions, Intravenous; Kidney Diseases; Kidney Glomerulus; Male; Platinum; Proteinuria	2001

Article

Year

Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.

Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:9

Topics: Adult; Aged; Antineoplastic Agents; Creatinine; Cyclobutanes; Erythrocytes; Female; Half-Life; Humans; Kidney Diseases; Liver Diseases; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Platelet Count; Platinum; Stereoisomerism

1999

Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions.

Pediatric nephrology (Berlin, Germany), 2001, Volume: 16, Issue:7

Topics: Adolescent; Antineoplastic Agents; Area Under Curve; Biomarkers; Child; Child, Preschool; Cisplatin; Female; Half-Life; Humans; Infusions, Intravenous; Kidney Diseases; Kidney Glomerulus; Male; Platinum; Proteinuria

2001

Other Studies

47 other study(ies) available for platinum and Kidney Diseases

Article	Year
Novel gold-platinum nanoparticles serve as broad-spectrum antioxidants for attenuating ischemia reperfusion injury of the kidney. Kidney international, 2022, Volume: 102, Issue:5 Topics: Antioxidants; Catalase; Cytokines; Fibrosis; Gold; Humans; Inflammasomes; Kidney; Kidney Diseases; Metal Nanoparticles; Oxidative Stress; Platinum; Reactive Oxygen Species; Reperfusion Injury	2022
Effect of Severe Renal Dysfunction on the Plasma Levels of DNA-Reactive Platinum after Oxaliplatin Administration. Biological & pharmaceutical bulletin, 2023, Volume: 46, Issue:2 Topics: Animals; DNA; Kidney Diseases; Oxaliplatin; Platinum; Rats	2023
Urinary transferrin pre-emptively identifies the risk of renal damage posed by subclinical tubular alterations. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 121 Topics: Acetylglucosaminidase; Animals; Biomarkers; Contrast Media; Creatinine; Disease Susceptibility; Female; Humans; Kidney Diseases; Kidney Tubules; Lipocalin-2; Male; Middle Aged; Platinum; Rats, Wistar; Risk Factors; Transferrin; Urea	2020
Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration. Life sciences, 2017, Nov-15, Volume: 189 Topics: Animals; Antineoplastic Agents; Cisplatin; Creatinine; Kidney Diseases; Magnesium Sulfate; Male; Organic Cation Transport Proteins; Organic Cation Transporter 2; Platinum; Rats; Rats, Wistar	2017
Hepatotoxicity, nephrotoxicity, and drug/chemical interaction toxicity of platinum nanoparticles in mice. Die Pharmazie, 2017, Jan-10, Volume: 72, Issue:1 Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Aspartate Aminotransferases; Blood Urea Nitrogen; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Cisplatin; Dose-Response Relationship, Drug; Drug Interactions; Interleukin-1beta; Interleukin-6; Kidney Diseases; Male; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Particle Size; Platinum	2017
Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients. Lung cancer (Amsterdam, Netherlands), 2018, Volume: 126 Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Genotype; Glucuronosyltransferase; Humans; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Small Cell Lung Carcinoma	2018
Luteolin ameliorates cisplatin-induced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney. Toxicology, 2013, Aug-09, Volume: 310 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Biomarkers; Blotting, Western; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Immunohistochemistry; Kidney; Kidney Diseases; Kidney Function Tests; Luteolin; Male; Mice; Mice, Inbred BALB C; Oxidative Stress; Platinum	2013
Role of CFTR in oxidative stress and suicidal death of renal cells during cisplatin-induced nephrotoxicity. Cell death & disease, 2013, Oct-03, Volume: 4 Topics: Animals; Benzoates; Biomarkers; Body Weight; Caspase 3; Cell Death; Cell Line, Tumor; Cell Survival; Cisplatin; Cystic Fibrosis Transmembrane Conductance Regulator; DNA Adducts; Enzyme Activation; Female; Glutathione; Humans; Intracellular Space; Kidney; Kidney Diseases; Kidney Tubules, Proximal; Mice; Oxidative Stress; Platinum; Rats; Rats, Wistar; Reactive Oxygen Species; Thiazolidines	2013
Efficacy and toxicity of cisplatin liposomes modified with polyethylenimine. Die Pharmazie, 2014, Volume: 69, Issue:4 Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Compounding; Drug Delivery Systems; Exocytosis; Humans; Indicators and Reagents; Kidney Diseases; Liposomes; Mice; Mice, Inbred ICR; Neoplasm Transplantation; Platinum; Polyethyleneimine	2014
Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients. Hematological oncology, 2017, Volume: 35, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Kidney Diseases; Lymphoma; Male; Middle Aged; Platinum; Recurrence; Retrospective Studies; Young Adult	2017
Vitamin E mitigates cisplatin-induced nephrotoxicity due to reversal of oxidative/nitrosative stress, suppression of inflammation and reduction of total renal platinum accumulation. Journal of biochemical and molecular toxicology, 2017, Volume: 31, Issue:1 Topics: Animals; Cisplatin; Inflammation; Kidney; Kidney Diseases; Male; Nitrosation; Oxidative Stress; Platinum; Rats; Rats, Wistar; Vitamin E	2017
Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy. BMC cancer, 2016, 09-23, Volume: 16, Issue:1 Topics: Aged; Aged, 80 and over; Anemia; Disease Progression; Europe; Female; Humans; Kidney Diseases; Liver Neoplasms; Male; Neoplasm Metastasis; Platinum; Practice Guidelines as Topic; Treatment Failure; Urinary Bladder Neoplasms; Urothelium	2016
Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents. Journal of pharmaceutical sciences, 2010, Volume: 99, Issue:6 Topics: Animals; Antineoplastic Agents; Cisplatin; Drug Delivery Systems; Female; Hyaluronic Acid; Injections, Intralymphatic; Kidney Diseases; Lymph Nodes; Lymphatic System; Platinum; Polymers; Random Allocation; Rats; Rats, Sprague-Dawley; Rodentia	2010
Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. The American journal of pathology, 2010, Volume: 176, Issue:3 Topics: Animals; Auditory Threshold; Blood Urea Nitrogen; Body Weight; Cation Transport Proteins; Cell Line, Tumor; Cisplatin; Cochlea; Copper Transporter 1; Ear Diseases; Glucose; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Male; Mice; Mice, Knockout; Organic Cation Transport Proteins; Organic Cation Transporter 2; Platinum; Protective Agents; Stria Vascularis	2010
Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. The Journal of pharmacology and experimental therapeutics, 2010, Volume: 335, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Urea Nitrogen; Blotting, Western; Cisplatin; DNA Adducts; Gene Expression; Gene Expression Regulation; Imidazoles; Immunohistochemistry; In Situ Nick-End Labeling; Inflammation; Kidney; Kidney Diseases; Mice; Mice, Knockout; Necrosis; NF-E2-Related Factor 2; Nucleic Acid Amplification Techniques; Oleanolic Acid; Platinum; RNA, Messenger; Transcription Factors	2010
Reduction of cisplatin-induced nephrotoxicity in vivo by selenomethionine: the effect on cisplatin-DNA adducts. Chemical research in toxicology, 2011, Jun-20, Volume: 24, Issue:6 Topics: Animals; Antineoplastic Agents; Antioxidants; Body Weight; Cisplatin; Creatinine; DNA Adducts; Drug Interactions; Kidney; Kidney Diseases; Liver; Male; Models, Molecular; Platinum; Rats; Rats, Wistar; Selenium; Selenomethionine	2011
Early onset of cisplatin-induced nephrotoxicity in streptozotocin-diabetic rats treated with insulin. Basic & clinical pharmacology & toxicology, 2004, Volume: 95, Issue:2 Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cisplatin; Diabetes Mellitus, Experimental; Drug Administration Schedule; Glycated Hemoglobin; Hyperglycemia; Injections, Intraperitoneal; Injections, Subcutaneous; Insulin, Isophane; Kidney; Kidney Diseases; Male; Platinum; Rats; Rats, Sprague-Dawley; Streptozocin; Time Factors	2004
Naringenin attenuates cisplatin nephrotoxicity in rats. Life sciences, 2005, Mar-18, Volume: 76, Issue:18 Topics: Animals; Antineoplastic Agents; Cisplatin; Flavanones; Kidney; Kidney Diseases; Kidney Function Tests; Male; Platinum; Rats; Urea	2005
Synthesis, physicochemical and in vitro pharmacological investigation of new platinum (II) complexes with some cycloalkanespiro-5'-hydantoins. European journal of medicinal chemistry, 2005, Volume: 40, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Cyclobutanes; Cycloheptanes; Epithelial Cells; Formazans; HL-60 Cells; Humans; Hydantoins; Kidney Diseases; Magnetic Resonance Spectroscopy; Mice; Molecular Structure; Organoplatinum Compounds; Platinum; Spectrophotometry, Infrared; Spiro Compounds; Tetrazolium Salts	2005
Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatric blood & cancer, 2006, Volume: 47, Issue:2 Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Hearing Loss, Sensorineural; Humans; Infant; Infusions, Intravenous; Kidney Diseases; Male; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Osteosarcoma; Platinum; Prospective Studies	2006
Comparative renal, hepatic, and bone marrow toxicity of Cisplatin and radioactive Cisplatin (191Pt) in Wistar rats. Cancer biotherapy & radiopharmaceuticals, 2006, Volume: 21, Issue:5 Topics: Animals; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Cisplatin; Female; Kidney Diseases; Platinum; Radioisotopes; Random Allocation; Rats; Rats, Wistar	2006
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Aug-15, Volume: 13, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Platinum	2007
[The effects of radium-224 in children and adults (author's transl)]. Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 1980, Volume: 128, Issue:9 Topics: Adolescent; Adult; Cataract; Child; Child, Preschool; Dwarfism; Eosine Yellowish-(YS); Exostoses; Humans; Infant; Kidney Diseases; Liver Diseases; Neoplasms, Radiation-Induced; Osteosarcoma; Platinum; Radium; Tooth Diseases; Tuberculosis	1980
Platinum drugs: combined anti-lymphoproliferative and nephrotoxicity assay in rats. Cancer chemotherapy and pharmacology, 1980, Volume: 4, Issue:4 Topics: Animals; Antineoplastic Agents; Cell Division; Hydrolysis; Kidney Diseases; Lymphocytes; Platinum; Rats; Time Factors	1980
[The protective effects of two hydration protocols against cisplatin nephrotoxicity]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 1994, Volume: 16, Issue:1 Topics: Adult; Breast Neoplasms; Cisplatin; Female; Furosemide; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Platinum	1994
Protection against cisplatin-induced nephrotoxicity in the rat by inducers and an inhibitor of glutathione S-transferase. Biochemical pharmacology, 1994, Aug-03, Volume: 48, Issue:3 Topics: Animals; Cisplatin; Glutathione Peroxidase; Glutathione Transferase; Isoenzymes; Ketoprofen; Kidney; Kidney Diseases; Liver; Male; Platinum; Rats; Rats, Wistar	1994
Correlation of total and interstrand DNA adducts in tumor and kidney with antitumor efficacies and differential nephrotoxicities of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin. Biochemical pharmacology, 1994, Aug-17, Volume: 48, Issue:4 Topics: Animals; Cisplatin; Cross-Linking Reagents; DNA; Fibrosarcoma; Kidney Diseases; Male; Mice; Mice, Inbred C3H; Organoplatinum Compounds; Platinum	1994
Reduced renal accumulation and toxicity of cisplatin in experimental galactosemia. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1993, Volume: 203, Issue:3 Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cisplatin; Diabetes Mellitus, Experimental; Diuresis; Galactosemias; Kidney Cortex; Kidney Diseases; Male; Platinum; Rats; Rats, Sprague-Dawley	1993
[Endovascular treatment of hemorrhagic renal angiomyolipoma with platinum microcoils]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1996, Volume: 6, Issue:3 Topics: Adult; Angiomyolipoma; Embolization, Therapeutic; Female; Hemorrhage; Humans; Kidney Diseases; Kidney Neoplasms; Platinum	1996
Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer chemotherapy and pharmacology, 1997, Volume: 40, Issue:4 Topics: Antineoplastic Agents; Cisplatin; Creatinine; Female; Humans; Kidney; Kidney Diseases; Logistic Models; Male; Neoplasms; Platinum; Retrospective Studies; Risk Factors	1997
Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Archives of toxicology, 1997, Volume: 71, Issue:11 Topics: Aging; Animals; Antineoplastic Agents; Ascorbic Acid; Blood Urea Nitrogen; Cisplatin; Female; Kidney Diseases; Lipid Peroxides; Male; Platinum; Rats; Rats, Wistar; Vitamin E	1997
Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats. Pharmaceutical research, 1999, Volume: 16, Issue:10 Topics: Animals; Anti-Arrhythmia Agents; Antineoplastic Agents; Area Under Curve; Biotransformation; Blood Urea Nitrogen; Calcium Channel Blockers; Cisplatin; Disopyramide; Kidney; Kidney Diseases; Liver; Male; Platinum; Rats; Rats, Wistar; Stereoisomerism; Verapamil	1999
Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: antioxidant defense system. Pharmacology & toxicology, 2000, Volume: 86, Issue:5 Topics: Animals; Antineoplastic Agents; Antioxidants; Catalase; Cisplatin; Creatinine; Dose-Response Relationship, Drug; Glutathione Peroxidase; Glutathione Reductase; Injections, Intraperitoneal; Kidney; Kidney Diseases; Lipid Peroxidation; Male; Malondialdehyde; Platinum; Rats; Rats, Wistar; Superoxide Dismutase; Thioctic Acid	2000
Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 300, Issue:1 Topics: Aminooxyacetic Acid; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blood Urea Nitrogen; Body Weight; Carbon-Sulfur Lyases; Cisplatin; Enzyme Inhibitors; gamma-Glutamyltransferase; Isoxazoles; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred C57BL; Platinum; Survival Analysis	2002
Cisplatin-induced loss of kidney copper and nephrotoxicity is ameliorated by single dose diethyldithiocarbamate, but not mesna. Toxicology and applied pharmacology, 1992, Volume: 112, Issue:2 Topics: Animals; Blood Urea Nitrogen; Body Weight; Cisplatin; Copper; Creatinine; Ditiocarb; Female; Kidney; Kidney Diseases; Mesna; Platinum; Rats; Rats, Inbred F344; Zinc	1992
Relative effectiveness of some compounds for the control of cisplatin-induced nephrotoxicity. Toxicology, 1991, Volume: 68, Issue:3 Topics: Animals; Carcinoma 256, Walker; Cisplatin; Drug Administration Schedule; Female; Kidney Diseases; Leukemia L1210; Mice; Mice, Inbred DBA; Platinum; Rats; Rats, Inbred Strains; Sulfur	1991
Nephrotoxicity of cisplatin, carboplatin and transplatin. A comparative in vitro study. Archives of toxicology, 1990, Volume: 64, Issue:5 Topics: Animals; Carboplatin; Cisplatin; Gluconeogenesis; Glucose-6-Phosphatase; In Vitro Techniques; Kidney Diseases; Male; Malondialdehyde; Microsomes; Organoplatinum Compounds; p-Aminohippuric Acid; Platinum; Rabbits; Rats; Rats, Inbred Strains; Species Specificity; Tetraethylammonium Compounds	1990
Cisplatin: nephrotoxic action in vertebrates and its prevention. Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology, 1989, Volume: 94, Issue:1 Topics: Animals; Choline; Cisplatin; Columbidae; Ethacrynic Acid; Female; Fishes; Furosemide; Kidney Diseases; Magnesium; p-Aminohippuric Acid; Platinum; Rana temporaria; Rats; Rats, Inbred Strains; Species Specificity; Urea; Uric Acid	1989
Protective effect of piperacillin against the nephrotoxicity of cisplatin in rats. Antimicrobial agents and chemotherapy, 1989, Volume: 33, Issue:4 Topics: Animals; Blood Urea Nitrogen; Cisplatin; Fosfomycin; Kidney; Kidney Diseases; Leukemia L1210; Male; Piperacillin; Platinum; Rats; Rats, Inbred F344	1989
Control of nephrotoxicity in the rat during repeated cis-platinum treatments. Journal of applied toxicology : JAT, 1989, Volume: 9, Issue:4 Topics: Animals; Cisplatin; Creatinine; Diuretics; Kidney; Kidney Diseases; Liver; Male; Platinum; Rats; Rats, Inbred F344; Thiocarbamates; Time Factors	1989
Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution. Cancer chemotherapy and pharmacology, 1988, Volume: 21, Issue:4 Topics: Animals; Cell Line; Cisplatin; Drug Carriers; Drug Compounding; Drug Resistance; Kidney Diseases; Liposomes; Lymphoma; Mice; Platinum; Rats; Spleen; Tissue Distribution; Tumor Cells, Cultured	1988
Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (iproplatinum, CHIP) in patients with normal and impaired renal function and following intraperitoneal administration. Medical oncology and tumor pharmacotherapy, 1988, Volume: 5, Issue:3 Topics: Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Kidney Diseases; Metabolic Clearance Rate; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Cavity; Platinum	1988
Inhibition of cis-diamminedichloroplatinum (II)--induced renal toxicity in the rat. Cancer chemotherapy and pharmacology, 1986, Volume: 17, Issue:1 Topics: Animals; Blood Urea Nitrogen; Carcinoma 256, Walker; Chelating Agents; Cisplatin; Creatinine; Female; Kidney; Kidney Diseases; Male; Platinum; Rats; Rats, Inbred F344; Rats, Inbred Strains	1986
An in vitro screening system for the nephrotoxicity of various platinum coordination complexes. A cytochemical study. Cancer chemotherapy and pharmacology, 1986, Volume: 17, Issue:3 Topics: Acid Phosphatase; Alkaline Phosphatase; Animals; Biological Transport; Diuresis; Histocytochemistry; In Vitro Techniques; Kidney; Kidney Diseases; Kidney Tubules; Male; Platinum; Rats; Rats, Inbred Strains; Sulfhydryl Compounds	1986
Histopathological study of human cisplatin nephropathy. Toxicologic pathology, 1986, Volume: 14, Issue:2 Topics: Adolescent; Adult; Aged; Biopsy; Blood Urea Nitrogen; Cisplatin; Creatinine; Diuresis; Electron Probe Microanalysis; Female; Humans; Kidney; Kidney Diseases; Kidney Tubules; Male; Middle Aged; Platinum; Tissue Distribution; Water	1986
Nephrotoxicity of cis-platin comparing young and adult rats. Pediatric research, 1986, Volume: 20, Issue:1 Topics: Aging; Animals; Cisplatin; Drug Administration Schedule; Glomerular Filtration Rate; Growth; Kidney; Kidney Diseases; Kidney Function Tests; Male; Platinum; Rats; Renal Circulation	1986
Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations. American journal of clinical oncology, 1985, Volume: 8, Issue:1 Topics: Cisplatin; Creatinine; Humans; Kidney Diseases; Platinum; Time Factors	1985